依那普利联合非洛地平对原发性高血压合并冠心病患者血压变异性及晚期氧化蛋白产物的影响OA

Objective:To investigate the effects of enalapril combined with felodipine on blood pressure variability(BPV)and advanced oxidation protein products(AOPP)levels in patients with essential hypertension and coronary heart disease(CHD).Methods:A total of 110 patients with essential hypertension and CHD who were treated at our hospital between July 2021 and December 2023 were enrolled.Using a random-number table method,patients were assigned to a control group(felodipine)or an observation group(enalapril plus felodipine),with 55 patients in each group.The following outcomes were compared between the two groups:BPV parameters,including mean daytime(d),nighttime(n),and 24-hour systolic blood pressure(SBP),diastolic blood pressure(DBP),systolic blood pressure coefficient of variation(SCV),and diastolic blood pressure coefficient of variation(DCV);AOPP levels;clinical efficacy;and adverse reactions.Results:After treatment,dSBP,nSBP,24 h SBP,dDBP,nDBP,24 h DBP,dSCV,nSCV,24 h SCV,dDCV,nDCV,24 h DCV,and AOPP levels decreased in both groups and were significantly lower in the observation group than in the control group(P<0.05).The overall response rate was significantly higher in the observation group than in the control group(94.55%vs.81.82%,P<0.05).The total incidence of adverse reactions did not differ significantly between the two groups(P>0.05).Conclusion:Enalapril combined with felodipine was effective in patients with essential hypertension and CHD,can reduce the expression levels of BPV and AOPP,and there was no increase in the risk of adverse reactions.